Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥18 years~* HIV-2 mono infection, confirmed by ELISA and Western Blot test or Immunoblot,~* antiretroviral treatment-naive, whatever the duration and indication of prior treatments,~* indication to treatment, with at least one of the following criteria : type B or C events, CD4 lymphocytes count below 500/mm3 at screening-visit or CD4 lymphocytes count decrease of at least 50 cell/µL/year over the last 3 years with the last CD4 lymphocytes count within -/+ 10 % of the nadir, plasma HIV-2 RNA load over or equal to 100 copies/mL at screening-visit,~* Pneumocystis prophylaxis if CD4 lymphocytes count below 200/mm3, combined to a toxoplasmosis prophylaxis in case of a positive toxoplasmosis serology,~* French residency for at least one year,~* Written informed consent, signed by the participant and the investigator (at the latest on the screening-visit and prior any study related intervention)~* Affiliate or beneficiary of a social security system (State Medical Assistance is not a social security scheme).~Exclusion Criteria:~* Absence of effective contraception method(women),~* Pregnancy, breastfeeding or wish for pregnancy during the trial,~* Curative treatment of a progressive opportunistic infection not compatible with those evaluated in the present study,~* Malignant or tumorous affection requiring chemotherapy or radiotherapy,~* Decompensated cirrhosis,~* Viral hepatitis C with a Metavir score over F2,~* Hemoglobinemia below 7g/dL, polynuclear neutrophils below 500/mm3, platelets below 50 000/mm3, creatinine clearance below 50 mL/mn, transaminase, alkaline phosphatase or bilirubin over 2.5N,~* Contraindication to one of the excipients of study treatments,~* Insuline-dependent diabetes mellitus not well controlled (with glycated haemoglobin (HbA1C) over 7%),~* Long-term corticosteroid treatment (more than 3 weeks of treatment),~* Judicial protection, legal guardianship,~* Participation in other therapeutic trial or comprising an exclusion period ongoing at the time of the screening-visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- raltegravir / emtricitabine / tenofovir disoproxil fumarate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).